Long-Term Debt (Quarterly)

Long-Term Debt: The sum of all long term debt fields.

Aquestive Therapeutics, Inc. (AQST) had Long-Term Debt of $27.52M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$13.02M
Net Income	$-31.86M
Cost of Goods Sold	$5.84M
Gross Profit	$7.18M
Operating Expenses	$41.85M
Operating Income	$-28.84M
Non-Operating Income/Expense	$-3.02M
Pre-Tax Income	$-31.86M
Normalized Pre-Tax Income	$-31.86M
Income after Taxes	$-31.86M
Income from Continuous Operations	$-31.86M
Consolidated Net Income/Loss	$-31.86M
Normalized Income after Taxes	$-31.86M
EBIT	$-28.84M
EBITDA	$-25.96M
Weighted-Average Shares Outstanding (Basic)	106.93M
Weighted-Average Shares Outstanding (Diluted)	106.93M
Earnings per Share (EPS) (Basic)	$-0.26
Earnings per Share (EPS) (Diluted)	$-0.26
Balance Sheet Financials
Current Assets	$149.27M
Property, Plant, and Equipment	$3.89M
Long-Term Assets	$11.16M
Total Assets	$160.43M
Current Liabilities	$47.61M
Long-Term Debt	$27.52M
Long-Term Liabilities	$146.48M
Total Liabilities	$194.09M
Common Equity	$-33.66M
Tangible Shareholders Equity	$-33.66M
Shareholders Equity	$-33.66M
Common Shares Outstanding	122.04M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-52.43M
Cash Flow from Investing Activities	$-0.56M
Cash Flow from Financial Activities	$102.62M
Beginning Cash	$71.55M
End Cash	$121.17M
Increase/Decrease in Cash	$49.62M
Stock-Based Compensation	$7.62M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.14
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-4.48
Debt to Equity Ratio	-0.82
Gross Margin	55.16%
Operating Margin	-221.58%
EBIT Margin	-221.58%
EBITDA Margin	--
Pre-Tax Profit Margin	-244.79%
Profit Margin	-244.79%
Free Cash Flow	$-52.99M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.95
Receiveable Turnover	0.73
Days Sales in Receivables	122.83
Return on Equity	94.65%
Return on Tangible Equity	94.65%
Return on Assets	-19.86%
Return on Investments	518.64%
Book Value Per Share	$-0.28
Free Cash Flow per Share	$-0.50
Operating Cash Flow per Share	$-0.49

Data from Zacks Investment Research, Inc.